Checkpoint Therapeutics, Inc. Submits Form 424B5 to SEC
Checkpoint Therapeutics, Inc. recently submitted a 424B5 form to the Securities and Exchange Commission, signaling an important development for the company. The filing indicates that Checkpoint Therapeutics, Inc. is planning to offer and sell a certain number of shares of its common stock in a public offering. Details such as the offering price and the intended use of the proceeds will be included in the final prospectus related to this offering.
Checkpoint Therapeutics, Inc. (0001651407) is a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer patients. The company’s pipeline includes targeted therapies for solid tumors and hematologic malignancies. For more information about Checkpoint Therapeutics, Inc., please visit their website.
The 424B5 form filed by Checkpoint Therapeutics, Inc. is a prospectus supplement related to a securities offering. This form provides additional information about the securities being offered and is filed by companies with the SEC to disclose pertinent details to potential investors. Investors can refer to the 424B5 form to make informed decisions about participating in the offering.
Read More:
Checkpoint Therapeutics, Inc. (0001651407) Files 424B5 Form with SEC
